Dalbavancin, oritavancin and telavancin: complete guide

Dalbavancin, oritavancin and telavancin are lipoglycopeptide antibiotics approved by FDA from 2009 to 2014. This guide covers their structure, mechanism, labeled uses, trials and warnings.

Complete guide6 min read

Key takeaway

FDA approved telavancin (Vibativ) on September 11, 2009, then dalbavancin (Dalvance) and oritavancin (Orbactiv) in 2014. In their skin infection trials, early response was 79.7% with dalbavancin versus 79.8% with vancomycin. It was 82.3% with oritavancin versus 78.9% with vancomycin. Only the Vibativ label has a boxed warning.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Vibativ on September 11, 2009.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited3 in this article · 3 across 1 article on Dalbavancin, oritavancin and telavancin
Related productsBPC-157, TB-500 and thymic peptides

Dalbavancin, oritavancin and telavancin are lipoglycopeptide antibiotics: relatives of vancomycin with an added fat-like side chain. This guide covers how they are built, how they kill gram-positive bacteria, their FDA-labeled uses, pivotal trials and label warnings. Sources were checked on November 17, 2026.

Quick answer: These three are prescription lipoglycopeptide antibiotics. Dalvance and Orbactiv are labeled for acute bacterial skin and skin structure infections. Vibativ is labeled for complicated skin infections and for hospital-acquired and ventilator-associated bacterial pneumonia. Vibativ carries a boxed warning on mortality, kidney toxicity and fetal harm.

Vitrapep does not sell dalbavancin, oritavancin or telavancin; this page is a reference summary of published research and regulatory information.

What are dalbavancin, oritavancin and telavancin?

All three are glycopeptides: a ring-linked chain of amino acids with sugars attached, like vancomycin. That amino acid core is why they count as peptides. The National Library of Medicine defines lipoglycopeptides as “glycopeptides that have an additional lipophilic side chains” (MeSH, 2019). The fatty tail helps these drugs cling to bacterial membranes. Our guide to peptide types covers how peptides are grouped.

Each is semisynthetic, meaning a natural product is chemically modified. The Dalvance label calls dalbavancin a “lipoglycopeptide antibacterial synthesized from a fermentation product of Nonomuraea species” (Dalvance label, 2025). ChEBI text in PubChem describes telavancin as vancomycin with a 2-(decylamino)ethyl group added (PubChem CID 3081362). ChEBI also says oritavancin is “functionally related to a vancomycin aglycone.”

Drugs@FDA lists the original approval of Vibativ (NDA 022110) on September 11, 2009. Dalvance (NDA 021883) followed on May 23, 2014, and Orbactiv (NDA 206334) on August 6, 2014. A second oritavancin product, Kimyrsa (NDA 214155), was approved on March 12, 2021 (Drugs@FDA).

Table 1

Dalbavancin, oritavancin and telavancin: key facts

Fact Dalbavancin Oritavancin Telavancin
Structure type Semisynthetic lipoglycopeptide Semisynthetic lipoglycopeptide Lipoglycopeptide derived from vancomycin
Class Lipoglycopeptide antibacterial Lipoglycopeptide antibacterial Lipoglycopeptide antibacterial
Molecular formula C88H100Cl2N10O28 C86H97Cl3N10O26 C80H106Cl2N11O27P
Molecular weight 1,816.7 g/mol 1,793.1 g/mol 1,755.6 g/mol
First FDA approval May 23, 2014 (NDA 021883) August 6, 2014 (NDA 206334) September 11, 2009 (NDA 022110)
Brand names (US) Dalvance Orbactiv, Kimyrsa Vibativ

Formulas and weights are from PubChem (dalbavancin, oritavancin, telavancin).

How do dalbavancin, oritavancin and telavancin work?

All three block the building of the bacterial cell wall. The Dalvance label says dalbavancin “interferes with cell wall synthesis by binding to the D-alanyl-D-alanine” end of the wall’s building blocks. That stops the cross-links that make the wall strong.

Oritavancin and telavancin add a second attack on the membrane. The Orbactiv label lists three actions. Two block the polymerization and cross-linking steps of wall building. The third is “disruption of bacterial membrane integrity, leading to depolarization, permeabilization, and cell death” (Orbactiv label, 2025). The Vibativ label says telavancin binds wall precursors, including lipid II, and “also binds to the bacterial membrane and disrupts membrane barrier function.” Compare daptomycin, which acts on the membrane alone.

What are dalbavancin, oritavancin and telavancin approved for?

The labels list these indications:

  • Dalvance (2014): adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria. These include Staphylococcus aureus (including MRSA), several streptococci and vancomycin-susceptible Enterococcus faecalis.
  • Orbactiv (2014): adult patients with ABSSSI caused by susceptible gram-positive bacteria, including S. aureus and Streptococcus pyogenes.
  • Vibativ (2009): adults with complicated skin and skin structure infections (cSSSI), and adults with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). For pneumonia, the label says it “should be reserved for use when alternative treatments are not suitable.”

What did the key trials show?

Dalbavancin (DISCOVER 1 and 2). Two identically designed, randomized noninferiority trials compared dalbavancin with vancomycin, with an option to switch to linezolid. The primary end point was early clinical response at 48 to 72 hours. Response was 79.7% (525 of 659) with dalbavancin and 79.8% (521 of 653) with the comparator. The weighted difference was −0.1 percentage points (95% CI, −4.5 to 4.2) (Boucher et al., 2014). The trials are registered as NCT01339091 and NCT01431339.

Oritavancin (SOLO I). This randomized, double-blind noninferiority trial compared oritavancin with vancomycin in 954 adults with skin infections. Its primary composite end point was met by 82.3% versus 78.9% (difference 95% CI, −1.6 to 8.4) (Corey et al., 2014). It is registered as NCT01252719.

Telavancin (ATTAIN). Two identical randomized, double-blind trials enrolled 1,503 patients with hospital-acquired pneumonia. Cure rates were 58.9% with telavancin and 59.5% with vancomycin among all treated patients. Among 654 clinically evaluable patients, they were 82.4% and 80.7% (Rubinstein et al., 2011). All three programs studied human patients.

What side effects does the label list?

The Vibativ label has a boxed warning. Patients with HABP/VABP and pre-existing moderate or severe kidney impairment had higher mortality with telavancin than with vancomycin. The warning also covers new or worsening kidney impairment and states that “VIBATIV may cause fetal harm” (Vibativ label, 2023). Its most common reaction in the pneumonia trials was diarrhea. In the skin trials, taste disturbance, nausea, vomiting and foamy urine were most common.

The Dalvance and Orbactiv labels have no boxed warning. Dalvance lists nausea, headache and diarrhea as its most common reactions. Orbactiv lists headache, nausea, vomiting, limb and skin abscesses, and diarrhea. Orbactiv also warns that it can interfere with some blood clotting tests and may raise bleeding risk with warfarin. All three labels warn of allergic reactions and C. difficile-associated diarrhea.

Resistance is a concern for the bacteria these drugs target. CDC estimated 323,700 MRSA cases in hospitalized U.S. patients in 2017, with 10,600 deaths (CDC, 2019). Each label also warns about the development of drug-resistant bacteria.

What is the regulatory status of these drugs, and how are they used in research?

All three are prescription drugs in the United States. Drugs@FDA lists AbbVie as the company for Dalvance and Melinta Therapeutics for Orbactiv and Kimyrsa. It lists Apotex for Vibativ, while the current DailyMed Vibativ label comes from Cumberland Pharmaceuticals.

The research summarized here is clinical: randomized human trials in skin infections and pneumonia. We found no documented role for these three drugs as laboratory reagents in the sources we checked.

Frequently asked questions about dalbavancin, oritavancin and telavancin

Are lipoglycopeptides peptides?

Yes. Like vancomycin, they have a ring-linked amino acid core with sugars attached. A fat-like side chain makes them lipoglycopeptides.

Which was approved first?

Drugs@FDA lists the original approval of Vibativ on September 11, 2009.

How do they differ from vancomycin?

They share vancomycin’s cell-wall target. Oritavancin and telavancin also disrupt the bacterial membrane, according to their labels.

Which one has a boxed warning?

Only Vibativ. Its warning covers higher mortality in some pneumonia patients with kidney impairment, kidney toxicity and possible fetal harm.

Are any approved for pneumonia?

Vibativ is labeled for HABP/VABP when alternative treatments are not suitable. Dalvance and Orbactiv are labeled for skin infections only.

What to know now

  • Structure: semisynthetic glycopeptides with a lipophilic side chain; 1,755.6 to 1,816.7 g/mol.
  • Approval: Vibativ 2009; Dalvance and Orbactiv 2014; Kimyrsa 2021; prescription only.
  • Mechanism: block cell-wall building; oritavancin and telavancin also disrupt membranes.
  • Evidence: 79.7% vs 79.8% (dalbavancin) and 82.3% vs 78.9% (oritavancin) versus vancomycin in skin infections.
  • Label: skin infections for all three; HABP/VABP for Vibativ only.
  • Safety: Vibativ boxed warning on mortality, kidney toxicity and fetal harm.

What we’re watching

Further revisions to the Dalvance, Orbactiv and Vibativ labels on DailyMed. CDC updates on MRSA. Related guides: vancomycin, daptomycin and echinocandins.

More for immune system

All 24 compounds for immune system

Sources: Allergan 2025, DALVANCE (dalbavancin) prescribing information; Melinta Therapeutics 2025, ORBACTIV (oritavancin) prescribing information; Cumberland Pharmaceuticals Inc 2023, VIBATIV (telavancin) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 021883 (DALVANCE); National Center for Biotechnology Information 2026; U.S. National Library of Medicine 2019, Lipoglycopeptides; Boucher 2014, The New England Journal of Medicine, 370; Durata Therapeutics 2011; Corey 2014, The New England Journal of Medicine, 370; Rubinstein 2011, Clinical Infectious Diseases, 52; Centers for Disease Control and Prevention 2019. All 11 citations

Back to the research library

References

  1. Allergan, Inc. (2025). DALVANCE (dalbavancin) prescribing information (revised 1/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b4674d8-4d1e-4728-8465-d42ada33fa5c
  2. Melinta Therapeutics, LLC. (2025). ORBACTIV (oritavancin) prescribing information (revised 2/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff09a726-9f9b-4e30-b509-396781293220
  3. Cumberland Pharmaceuticals Inc. (2023). VIBATIV (telavancin) prescribing information (revised 11/2023). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5359b759-db7c-4672-9e8a-59c93869bd91
  4. U.S. Food and Drug Administration. Drugs@FDA: NDA 021883 (DALVANCE), NDA 206334 (ORBACTIV), NDA 214155 (KIMYRSA) and NDA 022110 (VIBATIV). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021883, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206334, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214155 and https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022110
  5. National Center for Biotechnology Information. (2026). PubChem compound summaries for CID 16134627 (dalbavancin), CID 16136912 (oritavancin) and CID 3081362 (telavancin). Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16134627, https://pubchem.ncbi.nlm.nih.gov/compound/16136912 and https://pubchem.ncbi.nlm.nih.gov/compound/3081362
  6. U.S. National Library of Medicine. (2019). Lipoglycopeptides (MeSH descriptor D000077427). Medical Subject Headings. Retrieved November 17, 2026, from https://meshb.nlm.nih.gov/record/ui?ui=D000077427
  7. Boucher, H. W., et al. (2014). Once-weekly dalbavancin versus daily conventional therapy for skin infection. The New England Journal of Medicine, 370(23), 2169–2179. https://doi.org/10.1056/NEJMoa1310480
  8. Durata Therapeutics. (2011). Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ClinicalTrials.gov ID NCT01339091). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01339091
  9. Corey, G. R., et al. (2014). Single-dose oritavancin in the treatment of acute bacterial skin infections. The New England Journal of Medicine, 370(23), 2180–2190. https://doi.org/10.1056/NEJMoa1310422
  10. Rubinstein, E., et al. (2011). Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clinical Infectious Diseases, 52(1), 31–40. https://doi.org/10.1093/cid/ciq031
  11. Centers for Disease Control and Prevention. (2019, November 4). CDC’s 2019 antibiotic resistance threats report: Methicillin-resistant Staphylococcus aureus (MRSA). CDC Stacks. https://stacks.cdc.gov/view/cdc/83741